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IMPORTANCE It has not been established whether noninvasive ventilation (NIV) reduces the
need for invasive mechanical ventilation in patients who develop hypoxemic acute
respiratory failure after abdominal surgery.
OBJECTIVE To evaluate whether noninvasive ventilation improves outcomes among patients
developing hypoxemic acute respiratory failure after abdominal surgery.
DESIGN, SETTING, AND PARTICIPANTS Multicenter, randomized, parallel-group clinical trial
conducted betweenMay 2013 and September 2014 in 20 French intensive care units among
293 patients who had undergone abdominal surgery and developed hypoxemic respiratory
failure (partial oxygen pressure <60mmHg or oxygen saturation [SpO2]90%when
breathing room air or <80mmHgwhen breathing 15 L/min of oxygen, plus either [1] a
respiratory rate above 30/min or [2] clinical signs suggestive of intense respiratory muscle
work and/or labored breathing) if it occurred within 7 days after surgical procedure.
INTERVENTIONS Patients were randomly assigned to receive standard oxygen therapy (up to
15 L/min to maintain SpO2 of 94% or higher) (n = 145) or NIV delivered via facial mask
(inspiratory pressure support level, 5-15 cmH2O; positive end-expiratory pressure, 5-10 cm
H2O; fraction of inspired oxygen titrated tomaintain SpO294%) (n = 148).
MAIN OUTCOMES ANDMEASURES The primary outcomewas tracheal reintubation for any
cause within 7 days of randomization. Secondary outcomes were gas exchange, invasive
ventilation–free days at day 30, health care–associated infections, and 90-daymortality.
RESULTS Among the 293 patients (mean age, 63.4 [SD, 13.8] years; n=224men) included in
the intention-to-treat analysis, reintubation occurred in 49 of 148 (33.1%) in the NIV group
and in 66 of 145 (45.5%) in the standard oxygen therapy group within+ 7 days after
randomization (absolute difference, −12.4%; 95% CI, −23.5% to −1.3%; P = .03). Noninvasive
ventilation was associated with significantly more invasive ventilation–free days compared
with standard oxygen therapy (25.4 vs 23.2 days; absolute difference, −2.2 days; 95% CI, −0.1
to 4.6 days; P = .04), while fewer patients developed health care–associated infections
(43/137 [31.4%] vs 63/128 [49.2%]; absolute difference, −17.8%; 95% CI, −30.2% to −5.4%;
P = .003). At 90 days, 22 of 148 patients (14.9%) in the NIV group and 31 of 144 (21.5%) in the
standard oxygen therapy group had died (absolute difference, −6.5%; 95% CI, −16.0% to
3.0%; P = .15). There were no significant differences in gas exchange.
CONCLUSIONS AND RELEVANCE Among patients with hypoxemic respiratory failure following
abdominal surgery, use of NIV compared with standard oxygen therapy reduced the risk of
tracheal reintubation within 7 days. These findings support use of NIV in this setting.
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P ostoperative acute respiratory failure is a major con-tributor to the overall risk of surgery, leading to an in-crease inmorbidity andmortality.1-3 The early postop-
erative period following abdominal surgery is associatedwith
diaphragmatic dysfunction andadecrease in lungvital capac-
ity, whichmay lead to atelectasis formation and hypoxemia.4
Treating postoperative acute respiratory failure usually re-
fers to tracheal reintubation and invasive mechanical
ventilation.5 Tracheal reintubation for acute respiratory fail-
ure is associated with higher mortality and increased health
care utilization, with a longer duration of both intensive care
unit (ICU) and hospital stay.3 Reasons for the increase inmor-
tality include complications during the reintubationperiod6,7
and health care–associated infections such as pneumonia.6-9
This suggests that postoperative outcome may be improved
by strategies aimedat avoiding reintubation and invasiveme-
chanical ventilation.10
Noninvasive ventilation (NIV) has proven effective
in nonsurgical cases of acute exacerbation of chronic obstruc-
tive pulmonary disease11 and cardiogenic pulmonary
edema.12 However, to date, no evidence supports the use of
NIV in surgical patients with hypoxemic acute respiratory
failure after abdominal surgery. Indeed, NIV is sometimes
considered a relative contraindication after recent upper gas-
trointestinal tract surgery.13
To our knowledge, no multicenter randomized clinical
trials have evaluated whether NIV could reduce the need for
invasive mechanical ventilation and its effect on the inci-
denceofhealth care–associated infections inpatientswhode-
velop hypoxemic acute respiratory failure after abdominal
surgery.14,15
We hypothesized that application of NIVmay prevent re-
intubation and invasive mechanical ventilation and may de-
crease the rate of health care–associated infections.
We thus conductedamulticenter randomizedclinical trial
ofNIV in surgical patientswhodevelopedhypoxemicacute re-
spiratory failure after abdominal surgery, comparing NIV
against standard oxygen therapy.
Methods
Trial Design andOversight
The trial was an investigator-initiated, multicenter, strati-
fied, parallel-group trial with a computer-generated alloca-
tion sequence and an electronic system–based randomiza-
tion. The study protocol and statistical analysis plan
(Supplement 2 and Supplement 3) were approved for all cen-
ters by a central ethics committee in accordance with French
law. The trial was conducted in accordance with the Declara-
tionofHelsinki.Written informedconsent from thepatient or
consent from a relative was obtained on study inclusion. An
independent data and safety monitoring committee oversaw
the study conduct and reviewed blinded safety data, with in-
terim analyses performed after the inclusion of 100 and 200
patients. Patients were screened and underwent randomiza-
tionbetweenMay2013andSeptember2014at20French ICUs.
Randomization was performed centrally by the minimiza-
tionmethodwith theuseofacomputer-generatedandblinded
assignment sequence. Randomization was stratified accord-
ing to study site, age (<60 vs ≥60 years), site of surgery (up-
pervs lower abdominal), anduseofpostoperativeepidural an-
algesia, as this may influence outcomes.16
Patients
Patients were eligible for participation in the study if they
were older than 18 years and had undergone laparoscopic or
nonlaparoscopic elective or nonelective abdominal surgery
under general anesthesia. Patients were included if they met
the following criteria: a diagnosis of acute respiratory failure
occurring within 7 days of the surgical procedure,17,18 defined
as the presence and persistence for more than 30 minutes of
hypoxemia (defined by a partial oxygen pressure <60 mm Hg
when breathing room air or <80 mm Hg when breathing
15 L/min of oxygen or a peripheral oxygen saturation [SpO2]
≤90% when breathing room air plus either [1] a respiratory
rate higher than 30/min or [2] clinical signs suggestive of
intense respiratory muscle work and/or labored breathing,
such as use of accessory respiratory muscles, paradoxical
motion of the abdomen, or intercostal retraction). Exclusion
criteria were withholding of life-sustaining treatment,19 con-
traindications to noninvasive ventilation, sleep apnea syn-
drome, immediate tracheal intubation, requirement for an
emergent surgical procedure, and previous recruitment in
another trial.
Causes of Acute Respiratory Failure
We assigned causes of acute respiratory failure following ex-
tubation using adapted published definitions11,20-23 as fol-
lows: upper airway obstruction, aspiration or excess respira-
tory secretions, encephalopathy, congestive heart failure,
pneumonia, and atelectasis.
Study Interventions
Patientswere randomlyassigned to receive eitherNIVor stan-
dard oxygen therapy alone from randomization until day 30
or ICU discharge, whichever came first. Patients assigned to
standard oxygen therapy received supplemental oxygen at a
rate of up to 15 L/min to maintain an SpO2 of at least 94%. In
the interventiongroup,NIVwasdelivered througha facemask
connected to an ICU- orNIV-dedicatedventilator, using either
a heated humidifier or heat andmoisture exchanger to warm
and humidify inspired gases.24 Noninvasive ventilation was
started at an inspiratory positive airwaypressure of 5 cmH2O,
increasing to a maximum inspiratory pressure of 15 cm H2O,
aiming to achieve an expiratory tidal volume between 6 and
8mL/kgof predictedbodyweight and a respiratory rate lower
than 25/min. Positive end-expiratory airway pressure (PEEP)
was started at 5 cm H2O and increased as needed to a maxi-
mumof 10cmH2O.4,10PEEPand inspiredoxygen fractionwere
titrated to maintain an SpO2 of at least 94%. Ventilator set-
tings were subsequently adjusted as needed for patient
comfort.4 Patients in this group were encouraged to use NIV
for at least 6hours, continuously or intermittently, during the
first 24hours after randomization. BetweenNIV sessions, pa-
tients received standard oxygen therapy as described above.
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The use of high-flow oxygen nasal cannulas was not permit-
ted in either group. Any decision to discontinue NIV was left
to the attending physician. All other aspects of patient care in
both groups were conducted according to each center’s rou-
tine clinical practice.
Criteria for Reintubation
To reduce the risk of delayed reintubation and to ensure con-
sistency of indications for reintubation among all trial sites,
predefined criteriawere applied. Immediate reintubationwas
performed if patients hadanyof the followingpredefinedma-
jor clinical events: respiratory or cardiac arrest, respiratory
pauses with loss of consciousness or gasping for air, massive
aspiration, persistent inability to clear respiratory secretions,
heart rate of less than 50/min with loss of alertness, and se-
vere hemodynamic instability without response to fluid and
vasoactive drugs. After reintubation, all patients underwent
ventilation with the same ventilation protocol, using a
low-tidal-volume protective ventilatory strategy.25
Study Outcomes
The primary outcome for comparing NIV and standard oxy-
gen therapy was any cause of reintubation within 7 days fol-
lowing randomization. Causes and time to reintubation were
recorded. Secondary outcomes included gas exchange,
health care–associated infection rate within 30 days, number
of ventilator-free days (ie, days alive and without invasive
mechanical ventilation) between days 1 and 30, antibiotic use
duration, ICU and in-hospital length of stay, and 30- and
90-day mortality. Five of 7 secondary outcomes are reported
in this article. Definitions for each health care–associated
infection (pneumonia, urinary tract infection, central venous
catheter–related infection, bacteremia, and surgical site
infection, occurring both at least 48 hours after ICU admis-
sion and after study entry) are detailed in eAppendix 2 in
Supplement 1.
Statistical Analysis
We estimated that with a sample of 150 patients per group
evaluated for the primary efficacy outcome, the study had at
least 90% power to determine superiority of noninvasive
ventilation compared with standard oxygen therapy. For the
intention-to-treat analysis, the following assumptions were
made: a 65% event rate in the standard oxygen therapy
group10,26,27 and a 40% event rate in the noninvasive ventila-
tion group14,28,29 (absolute risk reduction with NIV of at least
25% based on expert opinion). Further assumptions (15% of
included patients) were made relating to patients random-
ized despite not being eligible for randomization according to
inclusion/exclusion criteria and loss to follow-up for the pri-
mary end point. Two interim analyses were conducted after
the first 100 and 200 patient randomizations by an indepen-
dent data and safetymonitoring committee for early stopping
of the study for safety (mortality within 90 days) using
Figure 1. Enrollment, Randomization, and Follow-up of Participants in the Noninvasive Ventilation for
Postextubation Respiratory Failure After Abdominal Surgery Study
535 Patients assessed for eligibility
via physical examination
235 Excluded
89 Enrolled in another study
46 Planned to return to operating
room for surgical reintervention
12 Attending physician did not
register for the protocol
26 Decision to withhold life-
sustaining treatment
31 Had sleep apnea syndrome
5 Under guardianship
9 Declined to participate
3 Younger than 18 y
3 Near death
8 No reason given
3 Had surgery >7 d prior
300 Randomized
150 Randomized to receive standard
oxygen therapy
145 Received standard oxygen therapy
as randomized
5 Did not receive standard oxygen
therapy
3 Withdrew consent for use of data
1 Under guardianship
1 Violation of exclusion criterion
(participation in another study)
150 Randomized to receive noninvasive
ventilation
148 Received noninvasive ventilation
as randomized
2 Did not receive noninvasive
ventilation
1 Withdrew consent for use of data
1 Violation of exclusion criterion
(noninvasive ventilation)
145 Included in primary analysis 148 Included in primary analysis
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a prespecified Haybittle-Peto efficacy boundary30 (α = .001
for the 2 interim analyses). A secondary modified intention-
to-treat analysis was performed for the primary outcome
including only patients who did not return to the operating
room for reintervention. Unadjusted χ2 testing was used for
primary outcome analysis. Multiple imputation was addi-
tionally performed if the frequency of missing data was
greater than 5%. A Markov chain Monte Carlo method was
used for the multiple imputation procedure; we generated
m = 5 complete data sets. Multiple logistic regression analysis
was used to identify relevant baseline covariates associated
with the primary outcome. Variables tested in the model
were selected if P<.15 and then presented as absolute differ-
ence for binary variables and mean differences for continu-
ous variables with 95% confidence intervals. Kaplan-Meier
curves for reintubation and for mortality rates were plotted
for the first 30 and 90 days, respectively, after inclusion in
the study and were compared by the log-rank test. We com-
pared the primary outcome in prespecified subgroups
defined by stratification criteria according to age (<60 vs ≥60
years), site of surgery (upper vs lower abdominal), and use/
nonuse of epidural analgesia. A 2-tailed P<.05 was consid-
ered to indicate statistical significance. SAS software, version
9.3 (SAS Institute Inc), was used for all analyses.
Results
Study Patients
From May 2013 through September 2014, 535 patients with
acute respiratory failurewithin7days followingabdominal sur-
gery were eligible, of whom 300 underwent randomization,
150tostandardoxygentherapyand150toNIV (Figure 1). Seven
patients were excluded after randomization because of with-
drawn consent (n = 4) or ineligibility (n = 3). Data on the pri-
mary outcome were available for all 293 remaining patients
(mean age, 63.4 [SD, 13.8] years; n = 224 men). Groups were
similar with respect to inclusion, site, duration of surgery,
Table 1. Patient Characteristics and Biomechanical Variables According to Study Group at Randomization
Characteristics
Standard Oxygen Therapy
(n = 145)
Noninvasive Ventilation
(n = 148)
Age, y
Mean (SD) 64.4 (13.1) 62.5 (14.5)
≥60, No. (%) 89/145 (61.4) 92/148 (62.2)
Male, No. (%) 108/145 (74.5) 116/148 (78.4)
Body mass indexa
Mean (SD) 27.1 (6.2) 27.2 (5.9)
>30, No. (%) 34/143 (23.8) 42/147 (28.6)
Simplified Acute Physiology Score II at study entry,
mean (SD)b
33.4 (11.7) 33.6 (12.8)
Sequential Organ Failure Assessment score
at study entry, mean (SD)c
4.5 (2.7) 4.3 (2.6)
Preexisting conditions, No. (%)
Current smoker 37/138 (26.8) 44/141 (31.2)
Alcohol abuse 26/142 (18.3) 23/141 (16.3)
Psychotropic use 16/144 (11.1) 15/147 (10.2)
Chronic hypertension 72/145 (49.7) 69/148 (46.6)
Ischemic heart disease 16/145 (11.0) 25/147 (17.0)
Chronic heart failure 4/143 (2.8) 7/146 (4.8)
Chronic obstructive pulmonary disease 18/143 (12.6) 29/148 (19.6)
Chronic kidney disease 9/145 (6.2) 5/147 (3.4)
Cirrhosis 26/145 (17.9) 23/147 (15.6)
Cancer 73/144 (50.7) 68/144 (47.2)
Sepsis 32/144 (22.2) 36/144 (25.0)
Clinical variables, mean (SD)
Body temperature, °C 37.3 (0.8) 37.3 (0.8)
Heart rate, /min 103.2 (19.6) 102.2 (18.6)
Respiratory rate, /min 28.8 (7.3) 28.2 (7.7)
Blood pressure, mm Hg
Systolic 135.6 (22.3) 132.8 (23.2)
Diastolic 68.7 (13.8) 70.1 (13.7)
Biochemical variables, mean (SD)
Hemoglobin, g/dL 10.7 (1.9) 11.0 (2.2)
Hematocrit, % 31.7 (5.7) 32.5 (6.4)
White blood cell count, ×103/μL 13.2 (6.8) 13.8 (9.3)
a Calculated as weight in kilograms
divided by height in meters
squared.
b The Simplified Acute Physiology
Score II is based on 17 variables;
scores range from0 to 163, with
higher scores indicating more
severe disease.
c The score on the Sequential Organ
Failure Assessment includes
subscores ranging from0 to 4 for
each of 5 components (circulation,
lungs, liver, kidneys, and
coagulation). Aggregated scores
range from0 to 20, with higher
scores indicating more severe
organ failure.
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causesofacuterespiratory failure, timefromsurgery, timefrom
extubation to acute respiratory failure (Table 1 and Table 2),
and gas exchange (Table 2 and eTable 1 in Supplement 1). The
initial settingswereas follows: for thestandardoxygen therapy
group, mean oxygen flow was 10.4 L/min (SD, 5.1 L/min); for
theNIVgroup,mean inspiratorypressurewas6.7 cmH2O (SD,
2.9 cmH2O),meanPEEPwas5.4 cmH2O (SD, 1.3 cmH2O), and
mean fraction of inspired oxygen was 50% (SD, 16%), result-
ing in amean tidal volumeof 8.3mL/kg (SD, 3.1mL/kg) of pre-
dicted body weight (eTable 2 in Supplement 1).
Outcomes
Primary Outcome
Noninvasive ventilation improved the primary outcome of
the 293 patients included in the intention-to-treat analysis;
reintubation occurred in 49 of 148 patients (33.1%) in the NIV
group and 66 of 145 (45.5%) in the standard oxygen therapy
group at 7 days after randomization (absolute difference,
−12.4%; 95% CI, −23.5% to −1.3%; P = .03) (Table 3, Figure 2,
and the eFigure in Supplement 1). The multivariable analysis
is shown in eTable 3 in Supplement 1, and NIV was signifi-
Table 2. Surgery and Acute Respiratory Failure Characteristics at Randomization
Characteristics
Standard Oxygen Therapy
(n = 145)
Noninvasive Ventilation
(n = 148)
Surgery
Recent surgical history, No. (%)
Elective 75/145 (51.7) 77/148 (52.0)
Emergency 70/145 (48.3) 71/148 (48.0)
Upper abdominal surgery, No. (%) 91/145 (62.8) 93/148 (62.8)
Type of surgery, No. (%)
Liver resection 39/143 (27.3) 40/140 (28.6)
Colorectal resection 38/143 (26.6) 30/140 (21.4)
Gastrectomy 18/143 (12.6) 16/140 (11.4)
Esophagectomy 9/143 (6.3) 14/140 (10.0)
Pancreaticoduodenectomy 13/143 (9.1) 11/140 (7.9)
Other procedures 26/143 (18.2) 29/140 (20.7)
Laparotomy surgery, No. (%) 131/144 (91.0) 134/146 (91.8)
Vertical midline incision 87/137 (63.5) 82/139 (59.0)
Transverse incision 43/137 (31.4) 48/139 (34.5)
Other 7/137 (5.1) 9/139 (6.5)
Laparoscopic surgery, No. (%) 16/144 (11.1) 16/145 (11.0)
Thoracotomy/laparotomy, No. (%)a 3/143 (2.1) 7/143 (4.9)
Epidural analgesia, No. (%) 21/145 (14.5) 23/148 (15.5)
Duration of surgical procedure, mean (SD), h 4.3 (2.7) 4.1 (2.6)
Extubated <6 h after end of surgery, No. (%) 90/145 (62.1) 94/148 (63.5)
Acute respiratory failure
Respiratory rate, mean (SD), /min 29 (7) 28 (8)
Time from end of surgery to acute respiratory failure,
mean (SD), d
2.6 (1.7) 2.4 (1.6)
Time from extubation to acute respiratory failure,
mean (SD), d
1.9 (1.6) 2.0 (1.6)
Time from acute respiratory failure to inclusion in study,
median (IQR), h
3.1 (1.0-8.7) 2.8 (1.0-7.3)
Causes of acute respiratory failure, No. (%)b
Atelectasisc 94/143 (65.7) 93/148 (62.8)
Tracheal secretions 54/143 (37.8) 58/148 (39.1)
Pneumonia 36/143 (25.2) 27/148 (18.2)
Pulmonary edema 23/143 (16.1) 21/148 (14.2)
Pleural effusion 19/143 (13.3) 18/148 (12.2)
Pulmonary embolism 11/143 (7.7) 6/148 (4.1)
Arterial blood gas at randomization,
mean (SD)
pH 7.41 (0.07) 7.42 (0.07)
PaO2:FIO2 ratio, mm Hg 188 (71) 201 (69)
PaCO2, mm Hg 37 (7) 39 (7)
HCO3, mmol/L 24 (4) 25 (4)
Abbreviations: FIO2, fraction of
inspired oxygen; IQR, interquartile
range.
a In these patients, 2 incisions were
made to perform the surgery, one
through the abdomen and one
through the thorax.
b Causes of acute respiratory failure
may bemultiple.
c Atelectasis was defined as lung
opacification with shift of the
mediastinum, hilum, or
hemidiaphragm toward the affected
area and compensatory
overinflation in the adjacent
nonatelectatic lung.
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cantly associated with reduced reintubation. Time from
inclusion to reintubation (Table 3) and reasons for reintuba-
tion (eTable 4 in Supplement 1) did not significantly differ
between the groups.
No significant difference was observed in the number of
patients requiring reintubation for reoperation (16/148 [10.8%]
in the NIV group and 16/145 [11%] in the standard oxygen
therapy group; P = .95).
In themodified intention-to-treat analysis includingallpa-
tients except those reintubated for reoperation (n = 261), NIV
also improved theprimaryoutcome.Reintubationoccurred in
33 of 132 patients (25.0%) in the NIV group and 50 of 129 pa-
tients (38.8%) in the standardoxygen therapy group (P = .02).
Secondary Outcomes
Among patients subsequently reintubated, patients who
received NIV spent less time under invasive mechanical ven-
tilation than patients treated with standard oxygen therapy
alone (Table 3). There were no significant differences
in gas exchange between groups (eTable 1 in Supplement 1).
At 30 days, compared with standard oxygen therapy, NIV
was associated with significantly more ventilator-free days
(25.4 vs 23.2 days; absolute difference, −2.2 days; 95% CI,
−0.1 to 4.6 days; P = .04). Patients treated with NIV also
experienced significantly fewer health care–associated infec-
tions (43/137 patients [31.4%] vs 63/128 [49.2%]; absolute
difference, −17.8%; 95% CI, −30.2% to −5.4%; P = .003),
especially less ICU-acquired pneumonia (20/137 patients
[14.6%] vs 38/128 [29.7%]; P = .003) (Table 3 and eTable 5 in
Supplement 1). Microorganisms causing pneumonia are
detailed in eTable 6 in Supplement 1. At 90 days, 22 of 148
patients (14.9%) in the NIV group and 31 of 144 (21.5%) in the
standard oxygen therapy group had died (absolute differ-
ence, −6.5%; 95% CI, −16.0% to 3.0%; P = .15) (Table 3 and
Figure 3).
Clinical Tolerance
Nosignificantdifferencewas seenbetween the2groups in the
overall incidence of serious adverse events (eTable 2 in
Supplement 1). Sevenpatients receivedNIV as rescue therapy
Table 3. Primary and Secondary Outcomes According to Study Group
Variables
Standard Oxygen
Therapy
(n = 145)
Noninvasive Ventilation
(n = 148)
Absolute Difference
(Noninvasive Ventilation −
Standard Oxygen Therapy),
% (95% CI) P Value
Outcomes, No./Total (%)
Primary outcome:
reintubation to day 7
66/145 (45.5) 49/148 (33.1) −12.41 (−23.51 to −1.31) .03
Secondary outcomesa
Reintubation to day 30 72/145 (49.7) 57/148 (38.5) −11.14 (−22.44 to 0.16) .06
Overall health
care–associated
infections to day 7
44/145 (30.3) 27/148 (18.2) −12.1 (−22.52 to −1.69) .02
Pneumonia to day 7 32/145 (22.1) 15/148 (10.1) −11.93 (−20.94 to −2.93) .005
Overall health
care–associated
infections to day 30
63/128 (49.2) 43/137 (31.4) −17.83 (−30.22 to −5.44) .003
Pneumonia to day 30 38/128 (29.7) 20/137 (14.6) −15.09 (−25.72 to −4.45) .003
30-Day mortality 22/144 (15.3) 15/148 (10.1) −5.04 (−13.32 to 3.24) .20
90-Day mortality 31/144 (21.5) 22/148 (14.9) −6.51 (−15.99 to 2.96) .15
90-Day mortality in
intubated patients
29/72 (40.3) 18/57 (31.6) −8.8 (−17.29 to 4.12) .31
Service Utilization, Median (IQR)
Days of invasive mechanical
ventilation over 30 d
0 (0-5) [n=145] 0 (0-3) [n=148] −0.93 (−2.51 to 0.64)b .05
Invasive ventilation–free
days to day 30c
30 (21.4-30) [n=145] 30 (25.9-30) [n=148] 2.22 (−0.11 to 4.55)d .04
Invasive ventilation–free
days to day 30 with
deceased accounting for 0
dc
30 (20.8-30) [n=145] 30 (25.9-30) [n=148] 2.30 (−0.33 to 4.93)d .04
Days in ICU to day 30 8 (5-15) [n=144] 7 (5-14) [n=146] −0.06 (−1.99 to 1.87) .80
Days in ICU to day 90 8 (5-15) [n=143] 7 (5-14) [n=146] 0.18 (−3.08 to 3.44) .45
Overall days in hospital to
day 90
25 (15-39) [n=130] 22 (14-35.5) [n=140] −2.39 (−7.68 to 2.91) .19
Days in hospital to day
90 (survivors only)
27 (16-43.5) [n=108] 20.5 (14-32) [n=114] −5.21 (−11.03 to 0.62)d .02
Time from inclusion to
reintubation, h
24 (0-72) [n=72] 48 (24-120) [n=57] 11.67 (−15.64 to 51.27) .31
Time from extubation to
reintubation, d
3 (2-5) [n=72] 4 (2-7.3) [n=60] 0.59 (−0.86 to 2.04) .14
Time from acute respiratory
failure to reintubation, d
1 (1-3) [n=72] 2 (1-6) [n=57] 0.66 (−0.76 to 2.09) .08
Abbreviations: ICU, intensive care
unit; IQR, interquartile range.
a For additional data on secondary
outcomes, see eTables 2, 3, 5, and 6
in Supplement 1.
b Log: −0.13% (95% CI, −0.49% to
0.22%).
c The number of invasive
ventilation–free days was defined as
the number of days without invasive
mechanical ventilation at day 30.
dBecause of nonnormal distribution
of some continuous variables, a
nonparametric analysis was used to
compare groups, but the 95% CI of
themean differencemay cross 0.
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in the standardoxygen therapygroup,ofwhom3(42.9%)were
subsequently intubated. There were 3 episodes of cardiac ar-
rest, 2 occurring before intubation (1 in the standard oxygen
therapy group and 1 in theNIV group). Tolerance and adverse
effects of NIV after the first trial in theNIV group are reported
in eTable 2 in Supplement 1.
Discussion
In thismulticenter randomizedclinical trial conductedamong
patients with hypoxemic acute respiratory failure after ab-
dominal surgery, noninvasive ventilation delivered via face
mask reduced the need for reintubation and for invasiveme-
chanical ventilation and was associated with fewer episodes
of health care–associated infection compared with standard
oxygen therapy.
Hypoxemia develops in 30% to 50% of patients after
abdominal surgery and can in some patients be well toler-
ated without symptoms.4,22,28 In others, however, hypox-
emia can progress to severe acute respiratory failure. The
genesis of hypoxemic acute respiratory failure postopera-
tively is multifactorial and partly related to atelectasis due
to hypoventilation and collapsed alveoli, retained secre-
tions, and diaphragmatic dysfunction.29,31 Atelectasis pro-
motes bacterial growth and increases lung permeability,
leading to pneumonia.32 In our study, NIV significantly
decreased overall health care–associated infections and
halved the rate of pneumonia. Noninvasive ventilation can
reverse loss of pulmonary volume through the combined
positive effects of PEEP and inspiratory pressure support,
which increase lung ventilation, reopen atelectatic alveoli,
and improve gas exchange.4 Reducing atelectasis by NIV
could also decrease bacterial growth, thus mitigating bacte-
rial translocation from the lung into the bloodstream.32
Avoidance of endotracheal intubation, bypassing the upper
airways, is probably the major reason for the pneumonia
reduction observed in patients treated by NIV.33 Moreover,
NIV has been shown to reduce overall nosocomial infection
rates through reduction in both the number and duration
of invasive devices such as intravenous and bladder
catheters.33 Finally, reducing health care–associated infec-
tions, especially pneumonia, could contribute to the trend
toward lower mortality observed in the NIV group (Table 3
and Figure 3).
Complications have been reported with NIV, such as gas-
tric distention and pulmonary aspiration. Noninvasive venti-
lation may also potentially impede patients’ ability to cough
and expectorate postoperatively. In the present study, no ad-
verse events were reported in either group. We did not ob-
serve higher morbidity and mortality in the NIV group, con-
trary to that reported inanotherpostextubation studybecause
of delayed reintubation in the NIV group.20 The selection of
appropriate postoperative patients who may benefit from
postextubation NIV is a key factor.4,34 One randomized clini-
cal study by Squadrone et al22 evaluated the use of noninva-
sive continuous positive airway pressure delivered via hel-
met after abdominal surgery. They studied 209 patients who
developed hypoxemia immediately after extubation without
necessarily having signs of respiratory distress. Nonetheless,
their earlyuseofnoninvasive continuouspositiveairwaypres-
sure significantlydecreased the incidenceof reintubation from
10%to1%.Our studypresents severaldifferences: (1)weevalu-
ated the efficacy of NIV deliveredwith facemask using 2 lev-
els of positive airwaypressure and (2)NIVwasusedas a thera-
peutic application in a more severe patient cohort with
hypoxemic acute respiratory failure and not prophylactically
in patients with hypoxemia alone. As a result, the respective
incidence of reintubation (standard oxygen therapy control
group rate of 10% for the study by Squadrone et al vs 45.5% in
the current study) and mortality (3% in the control group of
the study by Squadrone et al vs 22% in the current study) dif-
fered between the 2 studies (Table 3).
The strengthsof thepresent studyare its large sample size,
the selected population base, multicenter design, the explicit
criteria for reintubation, and a complete postoperative follow-
up.Baseline characteristics in the2groupswerewellmatched,
and the criteria for health care–associated infection diagnosis
are both validated and robust. The trial excluded patientswho
underwent another immediate surgical procedure, and strati-
ficationwasperformedaccording to study site, age, site of sur-
gery, and use/nonuse of postoperative epidural analgesia.
Figure 2. Cumulative Incidence of Reintubation Between Randomization
and Day 30 According to Study Group
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Figure 3. Probability of Survival Between Randomization and Day 90
According to Study Group
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Our studyhas several limitations. First, the observed rate
of reintubation in our study was lower than predicted in the
standard oxygen therapy group.2,3,17,35 This could be due, in
part, to exclusion of patients in whom acute respiratory fail-
ure was an early symptom of surgical complications needing
immediate reintervention.Althoughinvasiveendotrachealme-
chanical ventilation has remained the cornerstone of ventila-
tory strategy for severe acute respiratory failure for many
years,2 several studies have shown that mortality associated
withpulmonary complications is largely related to the risks of
postoperative reintubationandmechanical ventilation.2,3,36-38
Second, the present studywas not designed to showa signifi-
cant decrease in mortality in the NIV group. The lack of sig-
nificance for lowermortality observed in theNIV group (from
22% to 15% at day 90) could be due to an underpowered de-
sign. The lowmortality rate in the NIV groupmay result from
the cumulative effects of a decreased reintubation rate, a
shorter duration of invasivemechanical ventilation, and a re-
duced rate of health care–associated infections, especially
pneumonia (Table 3). Third, although we applied predefined
criteria for reintubation, bias cannot be completely ruled out
because blindingwith NIVwas not feasible. Fourth, the clini-
cally relevant effect size used in the power analysis was 25%.
Becausewewerenot able to identify randomizedclinical trials
that included similar patients, this was based on expert opin-
ion and was chosen to limit the likelihood of a type 1 error.
Recent high-impact trials have demonstrated the ben-
efits innonsurgical hypoxemic respiratory failure21 or equiva-
lence of high-flow nasal cannula compared with NIV in pa-
tients after cardiothoracic surgery with moderate to severe
hypoxemia.23 Future studies comparinguse of high-flowoxy-
gen cannula vs standard oxygen therapy andNIV for patients
after abdominal surgery as preventive (prophylactic)39 or cu-
rative application are needed.40
Conclusions
Among patients with hypoxemic respiratory failure follow-
ingabdominal surgery,useofNIVcomparedwithstandardoxy-
gen therapy reduced the risk of tracheal reintubation within
7 days. These findings support use of NIV in this setting.
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